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ABSTRACT
In utero hematopoietic stem cell transplantation (IUT) results in limited chimerism and tolerance to alloan-
tigens. We studied the relative role of B7.1 and B7.2 expression by dendritic cells (DCs) in engraftment and in
generating donor-specific tolerance in fetal mice. Mature dendritic cells (mDCs) from B7.1/ or B7.2/
donors and wild-type (WT) lineage-depleted (lin) C57BL/6 (B6) bone marrow (BM) were injected into
BALB/c fetuses. Six weeks after IUT, B7.1/ recipients had multilineage engraftment (4.7%  0.8% T cells
and 5.7%  1.1% granulocytes) associated with graft-versus-host disease (GVHD) and decreased survival, but
by 12 weeks only donor CD3 cells (2.1%  1.3%) were present. Recipients of B7.2/ mDCs and lin WT
B6 BM had exclusively CD3CD4 T cells (11.8%  8.5% at 6 weeks and 6.5%  2.5% at 12 weeks). Most
of the cells were T-helper 2, although 10.4%  1.4% were of the T-regulatory (Treg) phenotype, ie,
CD4CD25. Donor Treg cells were detected both in the thymus and spleen, thus suggesting an effect on both
central and peripheral immunity. The animals with Treg cells had better survival (82.3% versus 47.4%; P< .01)
and no GVHD (0% versus 65%; P < .001). This group alone demonstrated multilineage engraftment of donor
hematopoietic cells after postnatal transplantation with megadoses of donor lin BM. Both the engrafted donor
CD4CD25 and CD4CD25 cells induced comparable in vitro suppression of T-cell proliferation, thus
suggesting their role in the persistence of the donor T cells in vivo. The CD4CD25 cells produced
interleukin 10 or interleukin 4 and were inhibited by anti–T-helper 2 cytokine-neutralizing antibodies,
whereas the CD4CD25 cells showed no evidence of any involvement of a cytokine-like soluble mediator and
expressed cytotoxic T-lymphocyte antigen 4 (CTLA-4) and foxp3 constitutively. Donor mDCs and donor CD4
T cells were detected among the thymocytes of the recipients of B7.2/ mDCs and lin WT B6 BM. Thus,
it seems that costimulatory molecule expression of donor DCs can play a significant immunomodulatory role
in survival, GVHD, engraftment, and homing of allogeneic BM cells after IUT through the generation of Treg
cells.
© 2005 American Society for Blood and Marrow Transplantation
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lNTRODUCTION
Bone marrow transplantation (BMT) is the only
nown cure for many inherited marrow stem cell
efects, including hemoglobinopathies and severe im-
unodeﬁciency diseases. However, a successful BMT
enerally requires the administration of high doses of
mmunosuppressive and myeloablative therapy. Early n
B&MTn gestation, the fetal recipient is immunoincompetent
nd, thus, unable to reject allogeneic cells. Previous
xperiments have shown that in utero hematopoietic
tem cell transplants (IUT) during the ﬁrst or early
econd trimester in hematopoietically nondefective
ice, sheep, cats, and nonhuman primates result in a
ow level of donor cell engraftment [1-8]. Unfortu-
ately, although microchimerism can readily be
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6chieved, the low level of engraftment is insufﬁcient to
ure most diseases, and only a minority of engrafted
ecipients are tolerant to donor cells [9]. In human
ecipients of an IUT, durable donor cell engraftment
as occurred only in fetuses with severe combined
mmunodeﬁciency disease [10,11]. In murine models,
n addition to severe combined immunodeﬁciency dis-
ase, engraftment has been effective when a marrow
tem cell or progenitor cell defect was present [12].
We previously established a murine model of IUT
y using nondefective major histocompatibility com-
lex (MHC)–mismatched mice and showed that 70%
f animals engrafted and that MHC did not play a
ajor role early in gestation [1]. However, in this
odel, 0.1% donor cells could be found in the
irculation by 8 weeks of age, and only a minority of
nimals were tolerant to donor cells. However, we
ound that when C57BL/6 (B6) progenitor dendritic
ells (pDCs; CD80lowCD86CD11c) were coin-
ected with B6 bone marrow (BM) into gestational day
GD) 13 to 15 BALB/c fetuses, some of the recipients
ecame full donor hematopoietic chimeras, but many
eveloped graft-versus-host disease (GVHD) [8]. We
peculated that the pDCs were maturing in vivo and
ctivating donor T cells in the marrow preparation,
hus resulting in increased multilineage engraftment
nd GVHD, and we recently showed that sensitized
onor T cells could, in fact, mediate multilineage
ngraftment in utero [13].
T-cell activation is dependent on both an antigen-
peciﬁc T-cell receptor–based primary signal and an
ntigen-nonspeciﬁc costimulatory molecule–based sec-
nd signal. In the presence of the ﬁrst signal and
bsence of the second signal, the outcome is tolerance
n adult mice and monkeys [14-16]. A critical part of
he T-cell activation pathway is the interaction be-
ween CD28, expressed on resting T cells, and B7.1
nd B7.2, expressed on activated professional antigen-
resenting cells (APCs) [17,18]. Blockade of the B7.1/
7.2 interaction with CD28 signiﬁcantly prolongs al-
ograft survival and prevents GVHD in a variety of
nimal models [19-21].
To evaluate the effect of these 2 molecules, we
sed mature dendritic cells (mDCs) derived from
7.1/ and B7.2/ B6 mice and coinjected them
long with lineage-depleted (lin) B6 BM into GD 14
ALB/c fetuses. This created a situation in which
ild-type (WT) BM was presented to WT mis-
atched fetal cells by using donor mDCs that varied
nly in terms of B7 molecule expression. We found
hat donor B7.2/ mDCs and lin BM not only
esulted in prolonged graft survival and suppressed
mmunity to alloantigens, but also generated primarily
onor CD4 T cells, including CD25 cells in both
he spleen and thymus. These results indicate that
ostimulatory molecule expression of donor dendritic
ells (DCs) plays a signiﬁcant role in allogeneic en- p
58raftment and tolerance development and may even-
ually be useful in developing novel approaches to the
linical application of IUT for the correction of a
ariety of genetic diseases.
ATERIALS AND METHODS
ice
Adult BALB/c (H2d), C57BL/6 (H2b), and C3H
H2k) mice were purchased from Jackson Laboratories
Bar Harbor, ME). Breeding pairs of B7.1/ and
7.2/ B6 mice were a kind gift of Jeffery Bluestone
University of California-San Francisco) and Arlene
harpe (Harvard Medical School). Mice were main-
ained and bred in a pathogen-free environment in the
niversity of California-San Francisco Animal Care
acility by following the standard National Institutes
f Health guidelines for animal welfare under a pro-
ocol approved by the University of California-San
rancisco Committee on Animal Research. For timed
regnancies, we used estrus suppression in females by
rowding them, with subsequent acceleration by cag-
ng them with males. The day on which the vaginal
lug was identiﬁed was designated as GD 0.
hemicals and Reagents
Cells were cultured in complete culture medium
CCM) consisting of RPMI 1640 supplemented with
-glutamine (2 mmol/L/mL), nonessential amino ac-
ds (0.1 mmol/L/mL), sodium pyruvate (1 mmol/
/mL), 4-(2-hydroxyethyl)-1-piperazineethanesulfo-
ic acid (HEPES; 10 mmol/L), 2-mercaptoethanol
50 mol/L), gentamicin (50 g/mL), and 10% heat-
nactivated fetal bovine serum. BM and DCs were
arvested in collecting buffer that consisted of Dul-
ecco’s phosphate-buffered saline (DPBS) solution
ithout calcium and magnesium supplemented with
0 mmol/L HEPES, 2 mmol/L ethylenediaminetet-
aacetic acid, 50 g/mL gentamicin, and 2% heat-
nactivated fetal bovine serum. Recombinant mouse
ranulocyte-macrophage colony-stimulating factor
rmGM-CSF) and recombinant mouse interleukin
IL)–4 were purchased from R&D Systems (Minne-
polis, MN). Red blood cells were removed by os-
otic lysing buffer: 150 mmol/L ammonium chloride,
0 mmol/L sodium bicarbonate, and 1 mmol/L eth-
lenediaminetetraacetic acid (Sigma, St. Louis, MO).
reparation of lin BM and BM-Derived mDCs
Adult (10- to 12-week-old) male B6 mice (WT;
7.1/ or B7.2/) were used as the source of BM
nd DCs. BM was harvested by ﬂushing the femoral
nd tibial shafts with collecting buffer. Red blood cells
ere lysed with osmotic lysing buffer and washed 3 times
ith collecting buffer and CCM. The lin BM was
repared by depleting lineage-speciﬁc cell populations
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In Utero Transplantation of B7/ Dendritic Cells
Bith a cocktail of biotinylated monoclonal antibody
mAb; NK1.1, CD14, Gran, CD3, and B220; PharMin-
en, San Diego, CA) and streptavidin-coated magnetic
eads (Dynal Biotech, Delaware, NY) by following
he manufacturer’s instructions. The lin BM prepa-
ations contained 1% CD3 cells.
The method for the in vitro propagation of mDCs
as modiﬁed after that described by Inaba et al. [22]
nd Lu et al. [23]. For the generation of mDCs, 2 
06 BM cells were cultured for 6 days in 24-well plates
n CCM supplemented with 50 ng/mL rmGM-CSF
nd 10 ng/mL recombinant mouse IL-4. The medium
ontaining rmGM-CSF was refreshed every 2 days.
fter gentle swirling of the plates, half of the old
edium was aspirated, and an equivalent volume of
omplete medium with rmGM-CSF was added. At the
nd of the culture period, the nonadherent mononu-
lear cells were collected. To enrich for mDCs, the
uriﬁcation was performed in 2 steps. In the ﬁrst step,
he macrophages, natural killer cells, granulocytes,
ematopoietic stem cells, T cells, and B cells were
emoved from the culture by negative selection by
sing a cocktail of biotinylated mAb (NK1.1, CD14,
ran, c-kit, Sca-1, CD3, and B220) and streptavidin-
oated magnetic beads. The CD11c cells were then
urther puriﬁed by positive selection with anti-CD11c
nd a magnetic-activated cell sorter (Miltenyi Biotec,
uburn, CA). The enriched mDC preparation was
haracterized by ﬂow cytometry by using DC-related
ell-surface markers: CD11c, CD80, CD86, and
HC class II (PharMingen). In addition, we deter-
ined the presence of other cell lineages by pheno-
yping with CD3, B220, F4/80, natural killer, and
ran-1 mAb (PharMingen). The mDC preparations
ere 90% CD11cIa, whereas the mDC prepara-
ions from the B7.1/ mice expressed1% B7.1 and
20% B7.2, and the B7.2/ mice expressed 1.8%
7.2 and 78% B7.1.
n Utero Hematopoietic Stem
ell Transplantation
IUT was performed as previously described [8].
rieﬂy, GD 14 pregnant BALB/c mice were placed
nder general mask anesthesia with 2% isoﬂurane
Vet Equip Inc., Pleasanton, CA). The abdomen was
leaned with 70% alcohol, the uterus was exposed, and
he fetuses were injected intraperitoneally with 5 L
f the desired combination of lin BM and mDCs
ith a 50-L glass micropipette. In a preliminary
ose-response study with mDCs, we found that the
aximum tolerated number that we could inject into
he fetuses via the micropipettes was 150 000 cells.
hus, the cell numbers that were used for all of the
xperiments in this study were 1.5  105 mDCs and
.5  106 lin BM cells. After delivery, recipients
ere weaned at 21 days of age. Peripheral blood was
btained and analyzed by ﬂow cytometry beginning at w
B&MTweeks of age. Skin grafts were placed at 3 to 4
onths of age. At 6 to 9 months of age, recipient mice
ere anesthetized with isoﬂurane anesthesia and killed
y cervical dislocation. Blood and various tissues (see
elow) were collected for engraftment and histologic
valuation.
raft-versus-Host Disease
Recipients were monitored for survival, weight
ain, fur thickness, and rectal prolapse. Clinical signs
f GVHD at 15 days of age were graded as mild,
oderate, or severe according to previously described
riteria [13].
ollection of Blood and Tissues
Peripheral blood was drawn from the saphenous
ein and collected into heparinized microcapillary
ubes. Spleen, thymus, BM, liver, small and large in-
estine, and skin were obtained after death as previ-
usly described [8].
dentification of Engrafted Donor Cells
The percentage and subtype of donor cells were
valuated by 2- or 3-color ﬂuorescent cell-surface
taining with mAb and analyzed on a FACScan (Bec-
on Dickinson, San Jose, CA). The ﬂuorescein iso-
hiocyanate (FITC), phycoerythrin (PE), and Tricol-
r-conjugated rat or mouse anti-mouse mAb to mouse
acrophage (F4/80), granulocytes (gran-1), T cells
CD3e and CD4), B cells (B220), natural killer cells
pan DX-5), macrophages (F4/80), and donor cells
H2Kb) were purchased from PharMingen or Caltag
Burlingame, CA). FITC, PE, and Tricolor-conju-
ated hamster, rat, or mouse immunoglobulin (Ig)G1,
gG1, IgG1, IgG2a, and IgG2b isotype antibodies
ere used as controls. Red blood cells were lysed with
hole blood lysis reagent (Coulter Corporation, Mi-
mi, FL). Cells were washed twice with cold DPBS
ontaining sodium azide (0.1%) and 0.5% bovine se-
um albumin and incubated with Fc receptor blocker
t 37°C for 15 minutes. After 1 wash, the cells were
ncubated with the desired mAb cocktail in the dark
or 30 minutes. Parallel cultures were incubated with
sotype-matched nonspeciﬁc antibodies. Lymphocytes
ere gated on the basis of their forward- and side-
catter proﬁle for each experiment. Two-dimensional
isplays of FL1 versus FL2 or FL3 versus FL2 plots of
he gated population indicated the donor cell subtype
s identiﬁed by the CD antigens and H2Kb popula-
ions, respectively. BALB/c and B6 blood were used as
egative and positive controls, respectively. Donor
ell engraftment was deﬁned as 1% H2Kb cells on
he basis of results with nontransplanted BALB/c con-
rols.
For postmortem tissue evaluation of engraftment,
e used a modiﬁcation of a polymerase chain reaction
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6PCR) assay that has previously been described [1].
issue lysates were ampliﬁed for the target genes by
sing sequence-speciﬁc primers and sequence-speciﬁc
ligonucleotide probes [6,7]. Twenty-ﬁve microliters
f DNA lysate was added to 50 L of PCR mixture.
he following primers were used for H2Kb 1
mol/L of the primer pair KbB (CAC TAT TCA
GT GAT CTC T) and KbC (CCA GGT AGG
CC TGA GTC T).
-Regulatory and Thymic DC Studies
Pooled (3-6 animals per group) cryopreserved sin-
le-cell suspensions of thymocytes and splenocytes
ere thawed, and donor H2Kb cells were isolated by
sing biotinylated anti-H2Kb and streptavidin-coated
agnetic beads from Miltenyi Biotec. The puriﬁed
95.4%) donor cells were stained for T-regulatory (Treg)
ells by using mAb to H2Kb, CD4, CD25, cytotoxic
-lymphocyte antigen (CTLA)–4, and CD62L. The
2KbCD4CD25cells were sorted by using an
RIA (Becton Dickinson, Franklin Lakes, NJ) ﬂow cy-
ometer. Proteins were extracted from the sorted cells by
esuspending them in 350 L of lysis buffer contain-
ng 25 mmol/L 3[3-cholaminopropyl diethylammo-
io]-1-propane sulfonate, 250 mmol/L HEPES, and
5 mmol/L dithiothreitol. The protein concentration
as assessed in the supernatants by using the Bio-Rad
rotein Assay (Bio-Rad, Munich, Germany) by fol-
owing the instructions given by the manufacturer.
ive micrograms of protein was used per well to de-
elop a foxp3-speciﬁc enzyme-linked immunosorbent
ssay (ELISA) reaction. Brieﬂy, 5 g/mL total cellular
ntigen was diluted in standard coating buffer (100 L
er well) and added to an enhanced protein-binding
axisorb ELISA plate (Nalge NUNC, Rochester,
Y) and incubated overnight. The wells were
locked for 2 hours at room temperature with Tris-
uffered saline containing 0.05% Tween and 2%
ovine serum albumin and thereafter incubated
ith anti-mouse foxp3 mAb (e-Bioscience, San Di-
go, CA) at a concentration of 1 g/mL overnight
t 4°C. After washing 3 times with Tris-buffered
aline/0.05% Tween, the plate was incubated with
iotinylated rabbit anti-mouse (Dako, Hamburg,
ermany) for 1 hour at room temperature. After
ashing, the plate was incubated for 45 minutes
ith avidin-biotin-peroxidase complex. The plate
as developed with tetramethylbenzidine substrate
nd read at 490 nm.
For identifying donor thymic DCs, the puriﬁed
97.2%) donor thymocytes were stained for expression
f H2Kb, CD11c, MHC II, CD80, and CD86. In a
arallel tube, cells were stained for donor T cells and
D3, CD4, and CD8. 1
60ost-IUT Megadose BMT
To test for speciﬁc tolerance to donor hematopoi-
tic cells, we used a modiﬁcation of a protocol that has
een previously reported [24]. Brieﬂy, normal B6 mice
aged 6-8 weeks) were used as donors. BM was isolated
nd lineage depleted. A total of 40 106 lin BM cells
ere injected intravenously daily into adult IUT re-
ipients or age-matched controls for 5 successive days.
kin Grafting
We used a previously reported procedure for skin
rafting [8]. Brieﬂy, syngeneic, allogeneic (B6), and
hird-party (C3H) donor skin was used. The entire
raft bed and a small margin of surrounding tissue
ere covered with a double-thickness square of a non-
dherent pad supplemented with antibiotics, and the
ound was covered with a sheer bandage. After 9 days,
he bandage was removed, and grafts were scored daily
hereafter. Animals that rejected donor skin grafts
ithin 14 days of placement were classiﬁed as nontol-
rant.
ell Proliferation of Splenocytes
Different doses of DCs (5 104, 1 105, 2 105,
 105, and 8  105) isolated from B6 backgrounds
WT, B7.1/, and B7.2/) were used as stimulators
nd splenocytes from BALB/c as responders. Spleno-
yte suspensions were washed 3 times with CCM.
esponders (4  105) were cultured with allogeneic
timulator cells in 0.2 mL of CCM for 4 days in
6-well round-bottomed tissue culture plates in 5%
arbon dioxide in air. For the ﬁnal 18 hours, 40 L of
3H]thymidine (0.2 Ci) was added to each well. Cul-
ures were harvested onto glass ﬁber disks by using a
ultiple cell harvester. [3H]Thymidine incorporation
as determined in a liquid scintillation counter. Re-
ults were expressed as counts per minute (mean 	
D), stimulated minus resting.
nhibition Studies of Mixed Lymphocyte Reaction
[3H]Thymidine incorporation was used to quan-
itate the suppression assay. Varying numbers of
D4CD25 and CD4CD25 T cells were added
s regulatory cells to inhibit the allogeneic mixed
ymphocyte reaction (MLR) consisting of 4  105
ALB/c splenocytes and 8 105 irradiated B6 spleno-
ytes. The cells were cocultured in 0.2 mL of CCM
or 4 days in 96-well round-bottomed tissue culture
lates in 5% carbon dioxide in air. For the ﬁnal 18
ours, 40 L of [3H]thymidine (0.2 Ci) was added to
ach well. Cultures were harvested onto glass ﬁber
isks by using a multiple cell harvester. Results were
xpressed as counts per minute (mean 	 SD), stimu-
ated minus resting. Anticytokine antibodies (anti–IL-
0, anti–IL-4, and anti–transforming growth factor
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In Utero Transplantation of B7/ Dendritic Cells
BTGF]-
) were added to the cultures to study the
ffect of individual T-helper (Th)2 cytokines in facil-
tating the inhibition induced by Treg cells.
L-12 Determination
Culture supernatant was collected from B7.1/
nd B7.2/ mDCs with or without lipopolysaccha-
ide (LPS) stimulation. IL-12 p70 was measured by
ollowing the manufacturer’s instructions. Assays were
un in triplicate with standards ranging from 1000 to
6 pg in serial dilutions. The cytokine concentration
as extrapolated from the standards and expressed as
ean 	 SD.
etermining IL-2, IL-4, IL-10, and Interferon  in
D4CD25 T Cells
For the intracellular cytokine staining study, do-
or H2Kb cells were ﬁrst isolated with biotinylated
Ab and streptavidin magnetic beads. The cells were
tained for membrane CD antigens and intracellular
ytokine staining by following a previously published
rotocol [25]. Cells were cultured in RPMI 1640 with
0% fetal calf serum for 4 hours at 37°C in the
resence of 20 L of brefeldin A, a potent nontoxic
nhibitor of protein secretion (10 mmol/L; Sigma).
ells were harvested and stained for the surface ex-
ression of CD4/CD25 by using peridinin chlorophyll
rotein/Cy5 and FITC-conjugated anti-CD4 and an-
i-CD25 antibodies, respectively (PharMingen). After
ashing with DPBS containing 5% fetal calf serum
pH 7.2-7.4; GIBCO-BRL, Gaithersburg, MD), the
ells were treated and stained for their respective in-
racellular cytokines with the Fix and Perm kit
PharMingen) by following the manufacturer’s in-
tructions. All anti-cytokine antibodies were conju-
ated to PE. Samples were acquired in a FACSCaliber
Becton Dickinson), and data were analyzed and pre-
ented by using CellQuest Pro. Control samples were
ncubated with irrelevant, isotype-matched mAbs
PharMingen) in parallel.
igure 1. Proliferation of allogeneic (BALB/c) CD3 splenocytes in
, Mature DCs from WT B6 donors. B, Mature DCs from B7.1/ B6 d
B&MTtatistical Analysis
The Wilcoxon signed rank test and 2 analysis
ere used to analyze nonparametric data, and the
tudent 2-tailed t test was used for parametric data.
alues (2 tailed) of P  .05 were considered signiﬁ-
ant.
ESULTS
n Vitro Studies with B7.1/ and B7.2/ mDCs
Mature DCs from B7 knockout mice expressed Ia
ut had a reduced ability to stimulate allogeneic cells
n the MLR compared with WT mDCs (Figure 1).
hereas 103 mDCs from WT B6 donors maximally
timulated 105 BALB/c T cells, 4 times as many T
ells were needed for an equivalent response to 103
7.1/ mDCs. B7.2/ mDCs resulted in an even
ore muted response. We further characterized the
arious mDC preparations for in vitro production of
L-12 (Table 1). WT mDCs made increased IL-12 in
esponse to LPS (P .005), whereas mDCs from both
7.1/ and B7.2/ mice had only baseline IL-12
roduction in resting cultures, which increased signif-
cantly (P .05) in both B7.1/ and B7.2/ cultures
ith LPS exposure. Comparative IL-12 production by
DCs with LPS exposure shows that WT and
7.1/ mDCs produced similar amounts of IL-12
ut that B7.2/ mDCs produced signiﬁcantly less
L-12 (P  .003).
ole of Costimulatory Molecules in Survival,
ngraftment, and GVHD In Utero
Table 2 shows the results of IUT experiments in
hich WT B6 lin BM cells with or without B7.1/
r B7.2/ mDCs were injected into GD 14 BALB/c
etal recipients. The survival of recipients of B7.2/
DCs alone was approximately 80% (Table 2), which
s comparable to that seen with WT BM alone (Table
). However, recipients of lin WT BM and B7.1/
se to varying numbers of B6 mDCs from WT and knockout mice.respon
onors. C, Mature DCs from B7.2/ B6 donors.
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6DCs had a signiﬁcantly lower survival (P  .01)
ssociated with mild to moderate GVHD. None of
he recipients of B7.2/ mDCs and lin BM devel-
ped GVHD. In contrast, the recipients of WT
DCs and lin BM had the lowest live birth rate
mong all the groups studied, and none survived be-
ond 24 hours of birth (Table 2). Engraftment in
lood at 6 and 12 weeks of age is shown in Table 2. At
weeks after IUT, B7.1/ recipients had multilin-
age engraftment (4.7% 	 0.8% T cells and 5.7% 	
.1% granulocytes) in their blood, but by 12 weeks,
nly donor CD3 cells (2.1% 	 1.3%) were present.
he percentage of H2Kb (donor) T cells in the
lood of recipients of lin WT BM and B7.1/ was
elatively low (4.7% 	 0.8% and 2.1% 	 1.3%) at 6
nd 12 weeks of age, respectively, compared with
ecipients of lin WT BM and B7.2/ mDCs
11.8% 	 8.5% at 6 weeks [P  .001] and 6.5% 	
.5% at 12 weeks [P  .006]). However, in the recip-
ents of B7.2/ mDCs and lin BM, the CD3 cells
ere predominantly CD4 (Figure 2a), whereas the
-cell subset proﬁle of B7.1/ mDCs plus lin BM
howed a mixture of CD4 and CD8T cells with CD8
CD4 (data not shown). Neither of the groups that
eceived B7.1/ or B7.2/ mDCs alone showed any
ngraftment in blood or tissue. However, IUT recipients
f B7.1/ mDCs alone had transient low weight gain
nd patchy fur growth for the ﬁrst 3 weeks of life;
hese effects subsequently resolved.
haracterization of Engrafted Donor Cells
Splenocytes harvested from 2 IUT recipients of
7.2/ mDCs plus lin BM and donor H2Kb cells
ere selected by using biotinylated H2Kb mAb
PharMingen) and magnetically labeled streptavidin
Miltenyi Biotec). The cells were stained for CD4-
y5-PE, CD25 FITC, and 4 different cytokines (in-
erferon , IL-2, IL-4, and IL-10) by using PE-labeled
nti-cytokine antibody. The experiment was repeated
wice. The bulk of the circulating donor CD4 cells
ere Th2, as shown in Figure 2b. Analysis of the
ntracellular expression of the cytokines in these cells
uggested a predominance of Th2 versus Th1 cells, ie,
ncreased levels of IL-10 and IL-4, a small amount of
L-2, and very little interferon . Some of these CD4
ells were also positive for CD25, but the dual-positive
able 1. Estimation of IL-12 (pg/mL) in Dendritic Cell Culture Super
Hi GM* Hi GM  LPS† B7.1‡
160.6  30.2 887.3  108.7 56.8  22.8
Mature DCs (mDCs) generating by culture in high-concentration
LPS indicates lipopolysaccharide added to the culture (see “Mate
DCs from B7.1 or B7.2 knockout mice grown in high-concentrat
P  .003 versus B7.1  LPS.ells produced neither IL-10 nor IL-4 (Figure 2c). The e
62ngrafted donor cells were sorted into CD4CD25
nd CD4CD25 populations. MLR reactions were
stablished with B6 responders and B6, BALB/c, or
3H stimulators. To these cultures, different ratios of
he 2 CD4 cellular fractions were added. Both frac-
ions inhibited the T-cell proliferative response in the
LR, as demonstrated in Figure 3A. When anti-
ytokine neutralizing antibodies were added to the
ultures, it seemed that IL-10 and IL-4 had an impor-
ant role in the inhibition mediated by the
D4CD25 cells (Figure 3B). However, anti-cyto-
ine antibodies failed to reduce the inhibitory poten-
ial of the CD4CD25 cells (Figure 3C).
haracterization of Splenic Treg Cells of
onor Origin
Donor (H2Kb) cells isolated from pooled spleno-
ytes that had been harvested from IUT recipients of
7.2/ mDCs plus lin BM at 24 weeks of age were
valuated for the presence of Treg cells. A total of
6.7% of the H2Kb cells were CD4, and 4.3%
xpressed both CD4 and CD25 (Figure 4A). H2Kb
D4CD25 and H2KbCD4CD25 cells were
orted into separate tubes (75 000 cells per fraction),
nd foxp3 expression was determined. The ELISA (5
g/mL total cellular antigen) showed an optical den-
ity value of 0.005 	 0.001 (comparable to back-
round) for the CD4CD25 cells and 0.19 	 0.02
or the CD4CD25cells. The sorted cells were also
nalyzed for CTLA-4 expression, and the CD4
D25 fraction was found to be 73.3% CTLA-4
ositive (Figure 4B).
haracterization of Donor Cells in the Thymus
The donor cells in pooled thymuses from recipi-
nts of B7.2/mDCs and lin BM were analyzed for
1) thymic donor Treg cells (Figure 4C and D), (2)
hymic donor T-cell subset development (Figure 4E
nd F), and (3) thymic DCs (Figure 4G and H). The
arge majority (96.5%) of the donor cells in the thy-
us were CD3CD4, whereas only 1.06% were
on-CD3 cells of donor origin, presumably the donor
Cs (see below). Of the T cells, 84.1% expressed
D4, and 12.9% expressed both CD4 and CD25
Figure 4C). Of the sorted CD4CD25 cells, 75.9%
B7.1  LPS B7.2‡ B7.2  LPS
748.7  74.6 53.4  18.9 360.2  45.4§
-CSF (Hi)  recombinant mouse (rm) IL-4.
d Methods” for details).
GM-CSF plus rmIL-4.natants
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rials an
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Table 2. BALB/c Fetal Recipients of lin BM with or without mDCs from Eith
Recipient
Group Cells Injected
Fetuses
Injected
No.
Born
% Donor T Cells in Blood (Range)*
6 wk 12 wk
B7.1/ mDC  lin BM 38 23 4.7  0.8 (2.4-6.5) 2.1  1.3 (1.3-4.1)
mDC 10 7 0.5  0.2 (0.3-0.7) 0.1  0.1 (0.03-0.23)
B7.2/ mDC  lin BM 23 19 11.8  8.5§ (8.4-20.3) 6.5  2.5 (4.1-8.9)
mDC 10 8 0.2  0.1 (0.1-0.3) 0.1  0.1 (0.05-0.2)
lin BM lin BM 14 10 0.2  0.02 (0.08-0.3) 0.1  0.1 (0.05-0.2)
mDC WT mDC 11 6 — —
*Mean 	 SD percentage of donor T cells in blood of all surviving recipien nt at 6 weeks but just donor T cells at 12 weeks, and 13
of 23 B7.2/ mDC  lin BM recipients had T-cell engraftment only roups at 6 and 12 weeks of age.
†P  .01 versus B7.2/ mDC plus lin BM.
‡Six of 18 had multilineage engraftment (4.7% 	 0.8% T cells and 5.7% s.
§P  .001 versus B7.1/ mDC plus lin BM.
P  .006 versus B7.1/ mDC plus lin BM.
¶All animals died within 24 hours of birth.
In
U
tero
T
ransplantation
of
B
7

/
D
endritic
C
ells
663
B
B
&
M
Ter B7.1/ or B7.2/ Mice
No.
Surviving
at 6 wk No. Engrafted GVHD
18 (47.4%)† 6‡ Mild
7 (70%) 0 None
19 (82.3%) 13 None
8 (80%) 0 None
10 (100%) 0 None
0 (0%) Not evaluated¶ Not applicable
ts; 6 of 18 B7.1/ mDC  lin BM had multilineage engraftme
. Here only the T-cell data have been compared between all the g
	 1.1% granulocytes) at 6 weeks but just donor T cells at 12 week
i
f
t
t
m
f
8
w
v
T
T
p
g
i
u
t
t
a
T
p
t
a
c
p
d
m
m
b
w
s
s
B
p
l
a
j
o
B
W
c
m
e
t
B
e
B
a
p
s
H
m
e
p
s
b
5
p
c
B
B
c
r
(
t
a
h
t
B
i
c
F
e
T
a
s
p lated w
S. Bhattacharyya and M. J. Cowan
6ous tissues (Table 3). Although there was no evidence
or multilineage engraftment, phenotyping showed
hat there was engraftment of donor cells in the blood,
hymus, spleen, and BM of the recipients of B7.2/
DCs and lin BM. Furthermore, in the thymuses
rom these animals, there was an average of 13.4% 	
.3% donor cells (Table 3). Most of these donor cells
ere CD3 (data not shown). No engraftment was
isible in other recipient groups.
olerance
Mixed lymphocyte reaction. We measured recipient
-cell responses in the MLR to self, donor, and third-
arty stimulators. The results from 6 animals in each
roup evaluated in 2 separate experiments are shown
n Table 4. Compared with the response of BALB/c
ntransplanted controls, there was a signiﬁcant reduc-
ion in the MLR, speciﬁcally to B6 (donor) stimula-
ors, only in the recipients of either B7.2/ mDCs
lone or B7.2/ mDCs with lin WT BM (P  .01).
he response to a third-party stimulator (C3H) was
oor in all of the groups, including the BALB/c con-
rols (Table 4).
Skin grafting. We evaluated syngeneic, third-party,
nd allogeneic donor skin grafts in all groups of re-
ipients plus BALB/c controls (Table 5). We found
rolonged (rejection by day 36) selective acceptance of
onor skin grafts in 7 of 12 recipients of B7.2/
DCs and lin BM and in 2 of 5 recipients of B7.2/
DCs alone. All third-party C3H grafts were rejected
y day 14, and 80% of the BALB/c (self) skin grafts
ere permanently accepted.
Megadose postnatal BMT. To evaluate the in vivo
peciﬁcity of the reduced MLR that we saw in re-
ponse to donor stimulators in IUT recipients of
7/ mDCs with or without lin WT BM, we hy-
igure 3. Inhibition of the MLR by CD4CD25 and CD4CD
valuated as regulatory cells to inhibit the allogeneic MLR between
he experiment was repeated twice. A, Donor CD4CD25 versus
nticytokine antibodies (anti–IL-10, anti–IL-4, and anti–TGF-
) o
timulated with donor H2KbCD4CD25 T cells. C, Effect of an
roliferation of allogeneic (BALB/c) CD3 splenocytes when stimuothesized that tolerized animals would behave simi- t
64arly to recipients of megadoses of syngeneic BM with
n increase in multilineage engraftment [24]. We in-
ected a total of 200  106 male WT B6 lin BM cells
ver 5 days into adult IUT recipients of B7.1/ or
7.2/ mDCs with or without lin WT BM and
T age-matched allogeneic and syngeneic (female)
ontrols (Table 6). Mice that had received B7.2/
DCs and lin BM in utero showed multilineage
ngraftment in the blood 6 weeks after the megadose
ransplantation. In contrast, the in utero recipients of
7.1/ mDCs and lin BM showed no signiﬁcant
ngraftment (P  .05). Thus, the recipients of
7.2/ mDCs and BM cells, which had shown Th2
nd Treg-type engraftment after the primary trans-
lantation, showed multilineage engraftment in the
ubsequent megadose administration experiment.
owever, B7.1/ recipients at 6 weeks after the pri-
ary transplantation showed little to no multilineage
ngraftment with secondary postnatal megatrans-
lants with lin BM alone. A representative result is
hown in Figure 5, in which immunophenotyping of
lood for lineage identiﬁcation of donor cells (Figure
a and b) and detection of donor cells in tissues were
erformed by PCR ampliﬁcation (Figure 5c). Signiﬁ-
ant donor cell engraftment in the CD3, granulocyte,
-cell, and macrophage lineages can be seen in the
7.2/ mDCs plus lin BM recipients (Figure 5a)
ompared with the B7.1/ mDCs plus lin BMT
ecipients (Figure 5b). PCR analysis of various tissues
Figure 5c) shows the presence of donor cells only in
he recipients of B7.2/ mDCs plus lin BM. We
lso analyzed overall donor cell engraftment in various
ematopoietic tissues, ie, spleen, thymus, and BM of
he megadose recipients. Mice that had received
7.2/ mDCs and lin BM in utero showed signif-
cantly higher levels of engraftment (18%-42% donor
ells) in the marrow, spleen, and thymus 6 weeks after
-regulatory cells. CD4CD25 and CD4CD25 T cells were
/c splenocyte responders and irradiated B6 splenocyte stimulators.
CD25 T-cell fractions were cocultured in the MLR. B, Effect of
tro proliferation of allogeneic (BALB/c) CD3 splenocytes when
ine antibodies (anti–IL-10, anti–IL-4, and anti–TGF-
) on in vitro
ith donor H2KbCD4CD25 T cells.25 T
BALB
CD4
n in vi
ticytokransplantation, in contrast to the in utero recipients
F
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Bigure 4. Characterization of donor cell engraftment in pooled tissues (spleen and thymus) of IUT recipients of mDCs from B7.2/ B6 and
T lin BM from B6 donors. The percentage and subtype of donor cells were evaluated by 5-color ﬂow cytometry analysis and sorting.
, Donor (H2Kb) cells in spleen at the time of harvest: dot plot shows immunophenotyping of donor (H2Kb) cells in spleen,
D4-APC, and CD25/peridinin chlorophyll protein (PerCP)/Cy5. B, Further characterization of donor (H2KbCD4CD25) cells in
pleen by immunophenotyping for CTLA-4/PE. C, Donor (H2Kb) cells in the thymus at the time of harvest showing immunopheno-
yping of donor (H2Kb) cells in the thymus for CD4-APC and CD25-PerCP-Cy5. D, Further characterization of donor
H2KbCD4CD25) cells in spleen by immunophenotyping for CTLA-4/PE. The donor cells in the thymus were also analyzed for dendritic
ell and T-cell phenotype. E, Donor (H2Kb) cells in the thymus at the time of harvest. The dot plot shows CD3-APC versus H2Kb-FITC.
, Thymic CD3-APC gated cells plotted for CD4-PE versus CD8-APC-Cy7. G, Thymic donor dendritic cells in which H2Kb cells were
valuated for CD11c-PerCP-Cy5 versus MHC II/PE. H, Cells displaying high CD11c and MHC II were gated and plotted for CD80-APC
nd CD86-APC-Cy7.
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6f B7.1/ mDCs and lin BM, which had 2% to 5%
P  .05; Table 7).
The control animals were divided into syngeneic
nd allogeneic groups. The syngeneic controls were
ge-matched female BALB/c mice that received lin
M from male BALB/c animals. A quantitative real-
ime PCR was performed for the Y chromosome in
lood samples 6 weeks after transplantation. All recip-
ents showed high copy numbers of engrafted Y chro-
osome–positive cells in the blood (data not shown).
he allogeneic controls were age-matched BALB/c
ice that received lin BM from B6 mice. Quantita-
ive real-time PCR was performed for the H2Kb
arker in blood samples 6 weeks after transplantation.
here was no positive signal in any recipients, thus
ndicating rejection in age-matched allogeneic con-
rols (data not shown).
ISCUSSION
This study addressed the effect of B7 costimula-
ory molecule expression by donor DCs on recipient
n vivo and in vitro allogeneic responses to donor cells
fter IUT. The results support a role for Th2 and Treg
ells in the modulation of the immune response to
lloantigens in the fetal recipient. We found that
HC-mismatched mDCs from B7.2-deﬁcient mice,
hen coinjected with WT MHC-mismatched lin
M, were able to generate donor T cells postnatally.
urthermore, the B7 allele was critical in determining
he outcome after IUT. However, even though we
ound that coinjection of B7.2/ mDCs and lin BM
able 3. Engraftment of Donor Cells (Percentage H2Kb) in Various
Recipient Group* Blood
7.1/ mDC 0.03  0.04†
7.1/ mDC  lin BM 0.41  0.30
7.2/ mDC 0.11  0.13
7.2/ mDC  lin BM‡ 2.18  1.56
n  6 animals in each group.
Percentage of H2Kb cells, (mean 	 SD).
B7.2/ mDC  lin BM IUT recipients had signiﬁcantly high
(spleen), and P  .05 (bone marrow) versus B7.1/  lin BM
able 4. Recipient (BALB/c) T-Cell Responses to Alloantigen (MLR) a
Recipient Group* BALB/c†
7.1/ mDC 5.3  1.2‡
7.1/ mDC  lin BM 8.0  2.0
7.2/ mDC 3.4  0.2
7.2/ mDC  lin BM 3.7  1.9
ALB/c control 0.6  0.2
n  6 in each group, representing 2 separate experiments (3 mice
Stimulator cells.
Values are expressed as counts per minute (cpm)  103; stimulate
P  .001, B7.2/ mDC versus B7.1/ mDC; B7.2/ mDC 
P  .01, B7.2/ mDC  lin BM or B7.2/ mDC alone versus BALB
66nduces partial tolerance induction and development
f donor T cells, including Treg cells in both spleen
nd thymus, along with prolongation of graft survival
nd acceptance of secondary transplants, stable mul-
ilineage engraftment did not occur, and only donor T
ells could be identiﬁed after 6 weeks. This is consis-
ent with previous studies by us and others, in which it
as been shown that for long-term multilineage en-
raftment to occur, “space” was necessary in the re-
ipient marrow [13,26-28]. We also found that B7
xpression plays a signiﬁcant role in donor cell en-
raftment, survival, and GVHD after complete allo-
eneic mismatched IUT.
Numerous reports of IUT using allogeneic BM
lone in hematopoietically intact mice have docu-
ented microchimerism (1% donor cells) and lim-
ted tolerance induction (10% of animals) [9]. In
ddition, we have previously reported that coinjection
f WT donor pDCs with allogeneic BM leads to high
evels of donor cell engraftment [8]. We concluded
hat pDCs became mDCs in vivo, which activated
onor T cells, resulting in multilineage engraftment
nd GVHD [8,13]. We wanted to pursue the role of
7-CD28 signaling between APCs and donor T cells
n engraftment and tolerance induction of fetal mice
fter IUT. In this study, we addressed the effect of B7
ostimulatory molecule expression by donor DCs on
ecipient in vivo and in vitro allogeneic responses to
onor cells after IUT.
B7.2/ mDCs and WT lin BM resulted in the
ppearance of a signiﬁcantly higher number of donor
cells, a signiﬁcant reduction in the host allore-
at 6 Months after IUT
ymus Spleen Bone Marrow
 0.21 0.15  0.07 0.00  0.0
 0.14 0.08  0.06 0.09  0.05
 0.13 0.15  0.08 0.08  0.04
 8.3 2.73  2.06 3.12  2.8
tment in all tissues; P  .05 (blood), P  .001 (thymus), P  .05
ths after IUT
C57BL/6† C3H†
27.7  2.3 9.3  1.6
36.7  0.7 7.7  0.5
10.3  0.5§ 7.0  0.4
12.3  3.8§ 7.3  0.8
37.6  5.6 4.9  0.1
oup in each experiment).
sting (mean 	 SEM).
M versus B7.1/ mDC  lin BM.Tissues
Th
0.19
0.09
0.17
13.4
engraft 6 Mon
per gr
d  re
lin B/c control.
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Bponse, no GVHD, and normal survival. Further-
ore, these T cells were either of the Th2 type or
D4CD25. Additional studies revealed that the
D4CD25 cells were Treg cells because they con-
titutively expressed foxp3 and CTLA-4. The hypo-
esponsiveness generated selectively in the B7.2/
DC recipient group was seen in several ways, eg, in
itro MLR results, in vivo testing with skin grafts, and
ostnatal boosts. We found that although only donor
cells (Th2 and Treg) could be identiﬁed after 6
eeks after the primary transplantation with B7.2/
DCs and lin BM, multilineage engraftment oc-
urred after postnatal secondary megatransplantations
f lin BM. These results support a role for Th2 and
reg cells in the modulation of the immune response
o alloantigens in the fetal recipient.
In contrast, the B7.1/ mDCs and WT lin BM
esulted in the appearance of a small number of donor
cells associated with mild/moderate GVHD, no
eduction in host alloresponse, and signiﬁcantly re-
uced survival. The donor T cells that appeared in the
7.1/ mDC and WT lin BM recipients were pre-
ominantly CD8 cytotoxic cells. This indicates that
7 expression plays a signiﬁcant role in donor cell
ngraftment, survival, and GVHD after complete al-
ogeneic mismatched IUT.
Studies of the role of B7-CD28 interaction on
D4/CD8 homeostasis suggest that elimination of B7
ignaling leads to an increased proportion of CD4
ersus CD8 T cells at both the thymic and postthy-
ic levels [29]. Published results [30] and our own in
itro data show that silencing of B7.2 is more effective
han B7.1 in eliminating signaling in the fetal recipi-
nt. This alone might account for the CD4 subtype of
onor T cells that appeared with B7.2/ mDCs and
able 5. Acceptance or Rejection of Syngeneic, Donor, and Third-Party
Recipient Group BALB/c*
7.1/ mDC Accepted
7.1/ mDC  lin BM Accepted
7.2/ mDC Accepted
7.2/ mDC  lin BM Accepted
ALB/c control Accepted
Donor graft.
All rejections occurred by day 14.
Rejection at day 36.
able 6. Multilineage Engraftment in Blood 6 Weeks after Multiple M
Recipient Group* Animals Injected† T Ce
7.1/ 2 0.45 
7.2/ 6 3.2 
A total of 150, 000 B7.1/ or B7.2/ mDC plus 1.5  106 WT
Six weeks after IUT, recipient mice received 5 daily injections of
Percentage of donor (H2Kb) cells (mean 	 SD).
P  .05 versus the B7.1 recipient group.
B&MThe predominantly CD8 donor T cells that we saw in
he B7.1/ mDC recipient groups. Previous studies
ave shown that costimulatory molecule expression is
irectly correlated to the fate of engraftment, where
DC (MHChi, B7.1hi, B7.2hi, IL-12hi), semimature
C (MHChi, B7.1hi, B7.2lo, IL-12lo), and immature
C (MHClo, B7.1lo, B7.2lo, IL-12lo) phenotypes re-
ult in rejection, antigen-speciﬁc tolerance, and an-
rgy, respectively [31]. Thus, the B7.2/ mDC phe-
otype—ie, MHChi, B7.1hi, B7.2/, IL-12lo—and
unctional properties in effect mimic a semimature
C and, thus, might be responsible for the reduction
n alloreactivity across an MHC mismatch. Our study
as the distinct advantage of using genetically deﬁned
onor DCs, thus avoiding the possibility of in vivo
aturation and stimulation of these cells.
The reduced survival of the IUT recipients of
7.1/ mDCs and lin BM correlated with the in-
reased incidence of GVHD in these animals. When
e attempted to assess the outcome of IUT recipients
f WT MHC-mismatched mDCs, all of the mice died
ithin 24 hours of birth. The mechanism through
hich the recipients of B7.1/ mDCs and lin BM
eveloped GVHD is unclear, because the cell prepa-
ations were depleted of T cells. However, the surviv-
ng IUT recipients of B7.1/ mDCs alone or with
in BM all had reduced weight gain and patchy hair
oss that was very prominent in the ﬁrst few weeks of
ife. It was more severe when lin BM was coinjected
nd resolved as the mice aged and the donor CD3
umbers declined (data not shown). The percentage
f T cells present in the cell preparations was 0.5%
nd should not have induced GVHD-like conditions.
owever, it is possible that the B7.1/ mDCs were
imilar to WT mDCs in their ability to trigger an
rafts by BALB/c Recipients of mDCs with or without lin BM
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6lloreaction, as we saw in the in vitro experiments, and
he residual CD3 contamination (0.5%) in the mDC
reparations might have been enough to cause the
VHD. Another possibility is that the lack of expres-
ion of B7 on donor cells could have triggered an
utoimmune reaction in the fetal hosts. It is intriguing
hat studies of B7.1.2 double knockouts have found
ow levels of CD4CD25 Treg cells [32]; this is
igure 5. Donor cell engraftment in IUT recipients that underwe
onor cells were evaluated by ﬂow cytometry and PCR. A, Donor
in BM plus B7.2/ mDCs. B, Lineage analysis of donor (H2Kb
nd B7.1/ mDCs. C, PCR-ampliﬁed H2Kb products in WT B6
nd 8), blood (lanes 4 and 9), and bone marrow (lanes 5 and 10) of
lus B7.2/ mDCs (lanes 7-10).
able 7. Percentage Donor Cell Engraftment in Blood, Marrow, Spleen
UT Recipients
Recipient Group* Animals Injected† Blood
7.1/ 2 3.5  0
7.2/ 6 18.8  0
A total of 150, 000 B7.1/ or B7.2/ mDC plus 1.5  106 WT
Six weeks after IUT, recipient mice received 5 daily injections of
Percentage donor (H2Kb) cells (mean 	 SD).
P  .05 versus B7.1 recipient group.
68vidence that baseline expression of B7.1 and B7.2
olecules is required to prevent an autoimmune re-
ction and increased susceptibility to the development
f autoimmune disease [33]. In these studies, the B7
olecules were absent in all tissues and cells. How-
ver, in our studies, we found that the selective lack of
xpression of B7.2 only on donor APCs was able to
enerate Treg in vivo.
equent megadose transplantation. The percentage and subtype of
) cells in blood 6 weeks after mega-BMT in IUT recipients with
in blood 6 weeks after mega-BMT in IUT recipients with lin BM
splenocytes (lane 1) and in thymus (lanes 2 and 7), spleen (lanes 3
ecipients of lin BM plus B7.1/ mDCs (lanes 2-5) and lin BM
hymus 6 Weeks after 5 Megadose Transplantations into 6-Week-Old
Marrow Spleen Thymus
3.2  0.9 4.8  0.3 2.6  0.5
30.5  5.8§ 42.7  8.7§ 29.8  4.9§
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In Utero Transplantation of B7/ Dendritic Cells
BWe further characterized the engrafted cells to
ssess their regulatory potential. We found that most
f these cells were of the Th2 phenotype, secreting
oth IL-10 and IL-4. Although no intracellular cyto-
ine assays were performed for TGF-
, the results
ith anti–TGF-
 antibodies indicate a signiﬁcant role
or TGF-
 in this population. Treg suppresses the
mmune system by various pathways, but most in vivo
odels have identiﬁed IL-10 and TGF-
 as the most
igniﬁcant inhibitory molecules [34]. A small percent-
ge of the engrafted donor cells were CD425. Our
n vitro MLR studies with these engrafted CD4 cells
howed that both the CD25 and CD25 subsets had
nhibitory properties, with the former being “suppres-
or” cytokine mediated and the latter being cytokine
ndependent and more likely contact dependent [35].
hen we analyzed the ratio of double-positive, dou-
le-negative, single-positive, and single-negative thy-
ocytes of host and donor origin in pooled samples
rom in utero recipients of B7.2/ mDCs plus lin
M, we found a perfectly normal distribution of host
hymocyte subsets but an accumulation of donor
D4 cells. However, it is not clear whether these
reg cells are the cause or result of tolerance or an-
rgy. Because the engrafted cells have either a Th2 or
reg proﬁle, it is easy for these donor cells to survive
n the host long-term, because they will elicit the
owest immune response by the host. Our data also
ndicate that IL-10 producers are predominantly in
he CD4CD25 population. Prevention of lethal
VHD by infusion of donor CD4CD25 cells early
fter BMT has been achieved in haploidentical and
HC-matched, minor histocompatibility antigen–
isparate models [36]. Our results show the role of Treg
ells in alloengraftment in fetal recipients. Further stud-
es will be required to study whether there is any se-
uence of evolution of distinct T-cell populations.
We did not see multilineage engraftment in the
7.2/ mDC plus lin BM recipients after the pri-
ary transplantations. We believe that the exclusive
evelopment of donor CD4 cells after IUT with
7.2/ mDCs and WT lin BM is consistent with
he hypothesis that DCs (even in the presence of
onor stem cells) are unable to generate space in the
bsence of either donor T-cell activation or stem cell–
ytotoxic chemotherapy/radiotherapy. We believe
hat the selective reconstitution of the Th2 type of
D4 T cell prevented the subsequent development
f CD8 T cells. Without cytotoxic effector cells,
here was no mechanism for creating space [13]. How-
ver, the CD4 cells with Th2 and Treg properties also
nduced at least a partial tolerance in these animals.
his is supported by the megadose experiment, in
hich multilineage engraftment was seen in the
7.2/ mDC plus lin BM animals. The B7.1/
DC plus lin BM recipients, which had shown some
D8 engraftment, failed to show signiﬁcant engraft- t
B&MTent after megatransplantation. This indicates that
he costimulatory molecules of the donor mDCs play
role in tolerizing the recipients to the alloantigen.
he extent of total donor cell engraftment that we saw
n tissues of the B7.2/ mDC plus lin BM recipi-
nts after the megadose transplantation was compara-
le to what has previously been reported [24]. More-
ver, we saw multilineage engraftment in the blood of
he recipients of B7.2/ mDCs and lin BM; this
onﬁrms that they were tolerant to donor hematopoi-
tic cells.
At 6 months of age, the tissues, in particular, the
hymus, of the IUT recipients of B7.2/ mDCs and
in BM showed signiﬁcant donor cell engraftment;
his suggests that we were able to achieve at least
artial central tolerance. The identiﬁcation of donor
Cs in the thymus of the transplant recipients of
7.2/ mDCs and BM conﬁrms that the intraperi-
oneally injected donor cells were able to migrate to
he thymus, presumably via the host circulation. Re-
ently, donor murine thymic DCs injected intrave-
ously after partial T-cell depletion have been shown
o home to the thymus and prolong allograft survival
37]. Our approach is particularly promising in view of
he possibility that transient chimerism may be sufﬁ-
ient to induce transplant tolerance, which can subse-
uently be maintained by regulatory mechanisms.
The gradual loss of the transplanted cells in the
eripheral blood and the lack of permanent accep-
ance of the allogeneic skin graft in the B7.2/ mDC
nd lin BM recipients is comparable to IUT studies
onducted on congenic mouse strains [38]. In those
tudies, both allogeneic and congenic donor cells
radually decreased over time; however, the rate of
oss in congenic transplants was slower than that in
llogeneic transplants. Our results suggest that expo-
ure of the fetus to donor B7.2/mDCs results in the
ormation of donor Th2 cells (CD4CD25 and
D4CD25) in an allogeneic in vivo environment,
hich in turn makes the recipients tolerant through
he generation of Treg cells. Recent studies by Min et
l. [39] have also suggested the existence of a self-
aintaining loop between Treg and tolerogenic DCs.
In summary, we have shown that the coinjection of
HC-mismatched B7.2/ mDCs and WT lin BM
nto GD 14 fetal recipients results in the development
f signiﬁcant numbers of donor CD4 T cells with
h2 or regulatory properties in B7.2/ recipients
hat are likely responsible for reduced GVHD and
ncreased survival. The costimulatory molecule ex-
ression on the tolerogenic DCs affects survival,
VHD, and engraftment, and the MHChi, B7.1hi,
7.2/, IL-12lo phenotype is optimal for the reduc-
ion of the alloresponse, lack of GVHD, and survival.
he CD4 donor T cells that seem to mediate this
esponse are both CD25 and CD25, and their cy-
okine proﬁles are consistent with the Th2 subset of T
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6ells. However, although the engrafted donor Th2
ells seem to be durable in the host environment, they
re not sufﬁcient to establish multilineage engraft-
ent. For that to be achieved, space in the form of a
elective donor cell growth advantage will need to be
stablished, possibly with prenatal and/or postnatal
mmunotherapy [26,27]. The possibility of graft engi-
eering with excess B7.2-negative (maturation resis-
ant) DCs to generate antigen-speciﬁc anergy has sig-
iﬁcant potential in several clinical transplantation
pplications.
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